ストックスクリーナーアプリを入手
12.00
2.17%
0.255
プレマーケット:
11.75
-0.25
-2.08%
前日終値:
$11.74
開ける：
$11.73
24時間の取引高:
495.51K
Relative Volume:
0.95
時価総額：
$594.10M
収益：
-
当期純損益:
$-156.39M
株価収益率:
-3.252
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
+13.85%
1か月 パフォーマンス:
-3.92%
6か月 パフォーマンス:
-0.74%
1年 パフォーマンス:
+3.00%
1日の値動き範囲:
$11.73
$12.17
1週間の範囲:
$10.41
$12.35
52週間の値動き範囲:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
12.00 | 594.10M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com
(KALV) Trading Report - news.stocktradersdaily.com
Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World
Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle
The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter
KalVista: Poised For Rare Disease Transformation - Seeking Alpha
Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News
KalVista licensing deal with Kaken - The Pharma Letter
KalVista Pharmaceuticals (NASDAQ:KALV) Given “Buy” Rating at Needham & Company LLC - Defense World
KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia
KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa
KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology
KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical - TipRanks
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - BioSpace
KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan - marketscreener.com
KalVista stock rises on licensing deal in Japan (KALV:NASDAQ) - Seeking Alpha
Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan - MarketScreener
KalVista Pharmaceuticals, Inc. Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - marketscreener.com
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Humana (HUM) and PROCEPT BioRobotics (PRCT) - The Globe and Mail
Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World
Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
KalVista Strengthens Team with Strategic 87,000-Share Option Grant Package - Stock Titan
Where are the Opportunities in (KALV) - news.stocktradersdaily.com
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
Charles Schwab Investment Management Inc. Sells 10,372 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from Needham & Company LLC - Defense World
KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News
Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance
Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa
Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia
Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com
Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World
Kalvista stock holds as JMP reiterates $19 target - Investing.com
KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener
KalVista completes enrollment for pediatric HAE trial - Investing.com India
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - MarketScreener
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $23.80 Average Target Price from Analysts - Defense World
(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):